Antivenom efficacy, safety and availability: measuring smoke

• 1 Infectious Diseases Unit, Menzies School of Health Research, Casuarina, NT.
• 2 Department of Pharmacology, Australian Venom Research Unit, Parkville, VIC.

---

• 1. Chippaux JP. Snakebites: appraisal of the global situation. Bull World Health Organ 1998; 76: 515-524.
• 2. Cheng AC, Winkel KD. Snakebite and antivenoms in the Asia-Pacific: wokabaut wantaim, raka hebou (“walking together”). Med J Aust 2001; 175: 648-651. <MJA full text>
• 3. Theakston RD, Warrell DA. Crisis in snake antivenom supply for Africa. Lancet 2000; 356: 2104.
• 4. Theakston RD, Warrell DA, Griffiths E. Report of a WHO workshop on the standardization and control of antivenoms. Toxicon 2003; 41: 541-557.
• 5. Gawarammana IB, Kularatne SAM, Dissanayake WP, et al. Parallel infusion of hydrocortisone ± chlorpheniramine bolus injection to prevent acute adverse reactions to antivenom for snake bites. A randomised, double blind, placebo-controlled study. Med J Aust 2004; 180: 20-23. <MJA full text>
• 6. Fan HW, Marcopito LF, Cardoso JL, et al. Sequential randomised and double blind trial of promethazine prophylaxis against early anaphylactic reactions to antivenom for bothrops snake bites. BMJ 1999; 318: 1451-1452.
• 7. Premawardhena AP, de Silva CE, Fonseka MM, et al. Low dose subcutaneous adrenaline to prevent acute adverse reactions to antivenom serum in people bitten by snakes: randomised, placebo controlled trial. BMJ 1999; 318: 1041-1043.
• 8. Sutherland SK, Lovering KE. Antivenoms: use and adverse reactions over a 12-month period in Australia and Papua New Guinea. Med J Aust 1979; 2: 671-674.
• 9. Sutherland SK. Antivenom use in Australia. Premedication, adverse reactions and the use of venom detection kits. Med J Aust 1992; 157: 734-739.
• 10. Sutherland SK. Serum reactions: an analysis of commercial antivenoms and the possible role of anticomplementary activity in de-novo reactions to antivenoms and antitoxins. Med J Aust 1977; 1: 613-615.
• 11. Malasit P, Warrell DA, Chathavanich P, et al. Prediction, prevention, and mechanism of early (anaphylactic) antivenom reactions in victims of snake bites. BMJ 1986; 292: 17-20.
• 12. Winkel KD. Anaphylaxis associated with the same batch of tiger-snake antivenom [letter]. Med J Aust 2001; 174: 609-610.
• 13. National Centre for Classification in Health. Injury, poisoning and certain other consequences of external causes — 1923. Contact with venomous creatures. Australian coding standards for ICD-10-AM. Volume 5 of the International statistical classification of diseases and related health problems, 10th revision, Australian modification (ICD-10-AM). 3rd ed. Sydney: NCCH, 2002.
• 14. Manual de Diagnóstico e tratmento de acidentes por animais peçonhentos. Brasilia, DF: Ministério da Saúde. Fundação Nacional de Saúde, 1999.
• 15. Sutherland SK, Tibballs J. Treatment of snake bite in Australia: Chapter 17. In: Australian animal toxins. Melbourne: Oxford University Press, 2001: 312.
• 16. Currie B. Snakebite in tropical Australia, Papua New Guinea and Irian Jaya. Emerg Med 2000; 12: 285-294.
• 17. Product information: Australia New Guinea polyvalent snake antivenom. Parkville: CSL Limited, 2000.
• 18. Dart RC, McNally J. Efficacy, safety, and use of snake antivenoms in the United States. Ann Emerg Med 2001; 37: 181-188.
• 19. Lin RY, Curry A, Pesola GR, et al. Improved outcomes in patients with acute allergic syndromes who are treated with combined H1 and H2 antagonists. Ann Emerg Med 2000; 36: 462-468.
• 20. Theakston RDG, Warrell DA. Antivenoms: a list of hyperimmune sera currently available for the treatment of envenoming by bites and stings. Toxicon 1991; 29: 1419-1470.